Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Everolimus. Novartis.

F J Dumont1

  • 1Merck Research Laboratories, Department of Immunology & Rheumatology, 126 East Lincoln Avenue, PO Box 2000, Rahway, NJ 07065, USA. francis_dumont@merck.com

Current Opinion in Investigational Drugs (London, England : 2000)
|November 23, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BMS-188667 (Bristol-Myers Squibb).

IDrugs : the investigational drugs journal·2005
Same author

Treatment of transplant rejection: are the traditional immunosuppressants good enough?

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Alemtuzumab (Millennium/ILEX).

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

FK506, an immunosuppressant targeting calcineurin function.

Current medicinal chemistry·2000
Same author

Hypothemycin inhibits the proliferative response and modulates the production of cytokines during T cell activation.

Immunopharmacology·1999
Same author

C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: a tether length study.

Bioorganic & medicinal chemistry letters·1999
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Everolimus, an oral immunosuppressant for transplant rejection, faced patent challenges but received a favorable ruling from the European Patent Office. Financial forecasts predict significant sales growth for this novel therapeutic.

Area of Science:

  • Pharmacology and Immunology
  • Drug Development and Intellectual Property Law

Background:

  • Everolimus (RAD-001), an analog of sirolimus, is an oral immunosuppressant developed by Novartis.
  • It inhibits growth factor-induced cell proliferation and is under investigation for preventing transplant rejection.

Purpose of the Study:

  • To report on the development status, clinical trial progress, and patent litigation surrounding everolimus.
  • To provide sales forecasts for everolimus in the context of its therapeutic potential.

Main Methods:

  • Review of clinical trial initiation and progression for everolimus in transplant patients.
  • Analysis of patent infringement lawsuits and legal rulings concerning everolimus and its active ingredient.
  • Compilation of financial market analyst predictions for everolimus sales.

Related Experiment Videos

Main Results:

  • Phase III trials for everolimus were ongoing as of February 2001, with anticipated completion dates for different transplant types.
  • Patent litigation involved infringement claims and counterclaims, with mixed rulings in UK and Dutch courts, but a favorable decision on patent validity from the European Patent Office.
  • Financial analysts projected substantial sales growth for everolimus, with estimates ranging from SFr 80 million in 2002 to SFr 800 million by 2004.

Conclusions:

  • Everolimus demonstrated promising development progress and market potential, despite facing and overcoming patent disputes.
  • The European Patent Office's decision supported the inventiveness of Novartis's patent for everolimus.
  • Market forecasts indicate significant commercial success anticipated for everolimus in the immunosuppression market.